Jacobio Pharma Secures €172 Million: Concerns Over Collaboration Behind Ailis’ Massive Investment Exposed!

On September 27, 2024, Jacobio Pharma (stock code: 1167.HK) attracted a lot of attention in the industry when it officially announced a major cooperation development - the successful acquisition of Shanghai Ellis Pharmaceutical Technology Co., LTD. (stock code: 688578.SH) received up to 172 million yuan in cooperation funds. This payment not only marks the depth and stability of the cooperation between the two parties, but also demonstrates the excellent strength and extensive influence of Gax in the field of innovative drug research and development.

The composition of this cooperation is quite remarkable, including a down payment of 150 million yuan, which is a direct reflection of Ellis' high recognition and value of Gax's research and development results. In addition, there is also 22.79 million RMB as research and development cost compensation and other related payments, which will strongly support Gax's continued investment and innovation exploration in subsequent research and development projects.

Looking back at the history of cooperation between the two parties, it all began with the signing of a landmark cooperation agreement on August 30, 2024.This initiative not only shows CAx's trust and respect for its partners, but also reflects its firm determination to promote the development of China and even the global medical and health cause.

KRAS G12C inhibitor Golelexel, as a star drug in the field of tumor therapy in recent years, has won widespread praise worldwide for its unique mechanism of action and remarkable efficacy. The SHP2 inhibitor JAB-3312 is another effort of GaX in the field of precision medicine, and its precision strike ability for specific targets has brought new hope to many patients with refractory diseases. The introduction of these two drugs will undoubtedly inject new vitality into Ellis' product line and further consolidate its leading position in the pharmaceutical market.

It is worth noting that this cooperation not only reflects the depth of cooperation between the two sides in the field of drug research and development, but also indicates that China's pharmaceutical industry is gradually moving toward a new stage of internationalization and high-end. As the global pharmaceutical market continues to integrate and competition intensifies, Chinese pharmaceutical companies are enhancing their core competitiveness by strengthening international cooperation, introducing advanced technology and management experience. The cooperation between Gax and Ellis has undoubtedly set a new benchmark for the internationalization of China's pharmaceutical industry.